James Waisman

6.9k total citations · 1 hit paper
100 papers, 4.6k citations indexed

About

James Waisman is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James Waisman has authored 100 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 31 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James Waisman's work include Breast Cancer Treatment Studies (27 papers), HER2/EGFR in Cancer Research (21 papers) and Advanced Breast Cancer Therapies (19 papers). James Waisman is often cited by papers focused on Breast Cancer Treatment Studies (27 papers), HER2/EGFR in Cancer Research (21 papers) and Advanced Breast Cancer Therapies (19 papers). James Waisman collaborates with scholars based in United States, Switzerland and United Kingdom. James Waisman's co-authors include Melvin J. Silverstein, Bernard S. Lewinsky, William J. Colburn, Parvis Gamagami, Eugene D. Gierson, David Poller, Michael D. Lagios, Neal Handel, Pamela H. Craig and Alain Barth and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

James Waisman

96 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic classification of breast ductal carcinoma-in-situ

1995 503 citations David Poller, Melvin J. Silverstein et al. profile →

Peers

Countries citing papers authored by James Waisman

Since Specialization

Citations

This map shows the geographic impact of James Waisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Waisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Waisman more than expected).

Fields of papers citing papers by James Waisman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Waisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Waisman. The network helps show where James Waisman may publish in the future.

Co-authorship network of co-authors of James Waisman

This figure shows the co-authorship network connecting the top 25 collaborators of James Waisman. A scholar is included among the top collaborators of James Waisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Waisman. James Waisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer 2024 ·Cell Reports Medicine ·Lei Wang, Weihua Guo, (unknown), Jiangnan Yu, Jiayi Tan, Diana L. Simons, (unknown), Xinyu Liu, Qian Zhou, Yi-Zi Zheng, (unknown), John H. Yim, James Waisman, Peter P. Lee	46
2	Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis 2024 ·The Oncologist ·(unknown), (unknown), (unknown), Nora Ruel, Heather L. McArthur, James Waisman, Joanne Mortimer	9
3	A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling. 2024 ·Journal of Clinical Oncology ·(unknown), Colt A. Egelston, Susan E. Yost, Paul Frankel, (unknown), Christopher Ruel, Daniel Schmolze, Peter P. Lee, Christina Yeon, Yuan Yuan, James Waisman, Sumanta K. Pal, Joanne Mortimer	1
4	Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer 2024 ·Cancer Immunology Research ·Colt A. Egelston, Weihua Guo, Diana L. Simons, Jian Ye, Christian Avalos, Shawn T. Solomon, (unknown), Michael S. Nelson, Jiayi Tan, (unknown), (unknown), Daniel Schmolze, Lusine Tumyan, James Waisman, Peter P. Lee	2
5	Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment 2024 ·Nature Communications ·Weihua Guo, Jiayi Tan, Lei Wang, Colt A. Egelston, Diana L. Simons, (unknown), (unknown), Lu Wang, Shawn T. Solomon, James Waisman, Christina Wei, Caroline Hoffmann, Joo Y. Song, Daniel Schmolze, Peter P. Lee	5
6	Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer 2023 ·Journal of Clinical Medicine ·(unknown), Sayeh Lavasani, (unknown), (unknown), Mina S. Sedrak, Daphne Stewart, James Waisman, Yuan Yuan, (unknown), Raynald Samoa, Nora Ruel, Susan E. Yost, (unknown), (unknown), Joanne Mortimer	0
7	HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia 2023 ·Breast Cancer ·Michael Rainone, Carolyn E. Behrendt, Saro Kasparian, (unknown), Mina S. Sedrak, Sayeh Lavasani, Daphne Stewart, Yuan Yuan, Joanne Mortimer, James Waisman, Niki Patel, Vinod Pullarkat	3
8	Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer 2023 ·Cancer Immunology Immunotherapy ·Colt A. Egelston, Weihua Guo, Susan E. Yost, (unknown), Jin Sun Lee, Paul Frankel, Yujie Cui, Christopher Ruel, Daniel Schmolze, (unknown), (unknown), (unknown), Misagh Karimi, George Somlo, Peter P. Lee, James Waisman, Yuan Yuan	14
9	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer 2022 ·JCI Insight ·Colt A. Egelston, Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, (unknown), Yinghui Huang, Michael S. Nelson, (unknown), Daniel Schmolze, John H. Yim, Laura Kruper, Laleh G. Melstrom, Kim Margolin, Joanne Mortimer, Yuan Yuan, James Waisman, Peter P. Lee	25
10	Building a rapid autopsy program – a step-by-step logistics guide 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Peter P. Lee, James Waisman	6
11	Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care 2020 ·Journal of Clinical Medicine ·Joanne Mortimer, Laura Kruper, Mary Cianfrocca, Sayeh Lavasani, (unknown), (unknown), Mina S. Sedrak, (unknown), Daphne Stewart, James Waisman, Christina Yeon, Tina Wang, Yuan Yuan	3
12	Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer 2019 ·Nature Immunology ·Lei Wang, Diana L. Simons, Xuyang Lu, Travis Y. Tu, Shawn T. Solomon, Ruo‐Qian Wang, (unknown), Christian Avalos, Daniel Schmolze, John H. Yim, James Waisman, Peter P. Lee	125
13	Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study 2019 ·eScholarship (California Digital Library) ·Bihong T. Chen, (unknown), Sunita K. Patel, Ningrong Ye, Huiyan Ma, Chi Wah Wong, Russell C. Rockne, James C. Root, Andrew J. Saykin, Tim A. Ahles, Andrei I. Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, Daneng Li, Mina S. Sedrak, Jessica Vázquez, Vani Katheria, William Dale	1
14	IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer 2016 ·Cancer Research ·Lei Wang, Andrea K. Miyahira, Diana L. Simons, Xuyang Lu, Andrew Y. Chang, Carrie Wang, Maria Suni, Vernon C. Maino, Frederick M. Dirbas, John H. Yim, James Waisman, Peter P. Lee	37
15	Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism 2014 ·BMC Cancer ·(unknown), (unknown), (unknown), Peiguo Chu, Jinha Park, James Waisman, Joseph Kim	9
16	Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine (41.3) 2009 ·The Journal of Immunology ·Yushe Dang, Lupe G. Salazar, Andrew L. Coveler, James Waisman, Doreen M. Higgins, Jennifer S. Childs, (unknown), Meredith Slota, Mary L. Disis	1
17	Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity 2008 ·Molecular Cancer Therapeutics ·Vivian Goodell, James Waisman, Lupe G. Salazar, (unknown), John S. Link, Andrew L. Coveler, Jennifer S. Childs, Patricia A. Fintak, Doreen M. Higgins, Mary L. Disis	42
18	Bevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer 2007 ·Clinical Breast Cancer ·John S. Link, James Waisman, Bichlien Nguyen, (unknown)	26
19	Developing a prognostic index for ductal carcinoma in situ of the breast: Are we there yet? 1996 ·Cancer ·Melvin J. Silverstein, Pamela H. Craig, Michael D. Lagios, James Waisman, Bernard S. Lewinsky, William J. Colburn, David Poller	1
20	Hepatic injury due to oxacillin administration. 1978 ·PubMed ·(unknown), (unknown), James Waisman	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact